Evidence map›Paper›PMID 38792624›Full record

ArticleLife (Basel, Switzerland)2024

Everolimus Treatment for Chronic Lung Allograft Dysfunction in Lung Transplantation.

David Iturbe-Fernández, Alicia de Pablo Gafas, Víctor Manuel Mora Cuesta, Rodrigo Alonso Moralejo, Carlos Andrés Quezada Loaiza, Virginia Pérez González, Daniel López-Padilla, José M Cifrián

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

David Iturbe-FernándezLung Transplant Unit, Pulmonary Medicine Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Alicia de Pablo GafasLung Transplant Unit, Pulmonary Medicine Department, Doce de Octubre University Hospital, 28041 Madrid, Spain.
Víctor Manuel Mora CuestaLung Transplant Unit, Pulmonary Medicine Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.ORCID 0000-0002-8161-0462
Rodrigo Alonso MoralejoLung Transplant Unit, Pulmonary Medicine Department, Doce de Octubre University Hospital, 28041 Madrid, Spain.ORCID 0000-0002-7833-5084
Carlos Andrés Quezada LoaizaLung Transplant Unit, Pulmonary Medicine Department, Doce de Octubre University Hospital, 28041 Madrid, Spain.
Virginia Pérez GonzálezLung Transplant Unit, Pulmonary Medicine Department, Doce de Octubre University Hospital, 28041 Madrid, Spain.
Daniel López-PadillaPulmonary Medicine Department, Gregorio Marañón University Hospital, 28007 Madrid, Spain.
José M CifriánLung Transplant Unit, Pulmonary Medicine Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.ORCID 0000-0003-3682-0142

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our study aims to evaluate the effect of everolimus treatment on lung function in lung transplant (LT) patients with established chronic lung allograft dysfunction (CLAD).

methodsThis retrospective study included LT patients in two reference LT units who started everolimus therapy to treat CLAD from October 2008 to October 2016. We assessed the variation in the maximum forced expiratory volume in the first second (FEV

resultsFifty-seven patients were included in this study. The variation in the FEV

conclusionsThis study showed an improvement in FEV

Indexed as

chronic lung allograft dysfunctioneverolimuslung transplantation

Identifiers

PMID38792624
PMCPMC11123303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.